Disjointed: Cell Differences May Explain Why Rheumatoid Arthritis Varies By Location

Findings point to new approaches in targeted therapies so that what works for arthritic hands may not be the same for ailing hips —

Researchers at the University of California San Diego School of Medicine, with colleagues in Pennsylvania and China, report that not only are there distinct differences in key cellular processes and molecular signatures between rheumatoid arthritis (RA) and osteoarthritis (OA) but, more surprisingly, there are joint-specific differences in RA. The findings help explain, in part, why drugs treating RA vary in effect – why, for example, a treatment that might work in arthritic knees isn’t effective in an arthritic hip – and provide a potential new template for precisely targeting treatment for each and every ailing joint. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary S. Firestein

Gary S. Firestein, MD, Professor of Medicine in the Division of Rheumatology, Allergy & Immunology, is co-corresponding author of the study report with Wei Wang, PhD, professor in the departments of Chemistry and Biochemistry and Cellular and Molecular Medicine at UC San Diego.

Dr. Firestein is Director of the Clinical and Translational Research Institute (CTRI) and Dean and Associate Vice Chancellor of Translational Medicine for UC San Diego.

A Department of Medicine faculty coauthor of the report is David L. Boyle, Professor of Medicine in the Division of Rheumatology, Allergy & Immunology and Co-Director, Translational Research Technology, CTRI.

Read the study report (UC San Diego Only)

UC San Diego Part of New Effort to Fight Autoimmune Disorders

Major multi-year partnership will focus first on rheumatoid arthritis and lupus

The Division of Rheumatology, Allergy and Immunology at University of California, San Diego School of Medicine has been named a key site in a national, multi-institution, multi-year $41.6 million program to speed drug discovery, development, diagnostics and therapies for patients with autoimmune disorders, primarily rheumatoid arthritis (RA) and lupus erythematosus, which affect millions of Americans. …Read the full story from the UC San Diego Newsroom

Study Identifies Potential New Class of Drug for Treating Ulcerative Colitis

Oral Drug Shows Clinical Response and Remission in Some Patients

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM). … Read the full story from the UCSD Newsroom


Dr. William J. SandbornThe principal investigator of the study is Dr. William J. Sandborn, professor of medicine and chief of the Division of Gastroenterology at UCSD.  |  Read his academic profile  |  Read his clinical profile

Read the abstract of the study report in the New England Journal of Medicine

Citation of study report:  Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616-24.

Dr. Gary Firestein Honored with 2010 Jane Wyman Humanitarian Award

Dr. Gary Firestein

Gary S. Firestein, MD, Professor of Medicine, Dean and Associate Vice Chancellor of Translational Medicine and Director of the Clinical and Translational Research Institute at the University of California, San Diego School of Medicine, has been named the 2010 recipient of the prestigious Jane Wyman Humanitarian Award from the Arthritis Foundation, Pacific Region.

This award recognizes Firestein’s “affiliation with the Arthritis Foundation and its mission, and his extraordinary leadership in rheumatology and philanthropy in the community.”

The award will be presented at the foundation’s Commitment to a Cure Gala at the Beverly Wilshire Hotel in Beverly Hills on November 1. Past recipients of the Jane Wyman Humanitarian Award have included Victoria Principal; Sarah Purcell; Kathy Ireland; William Friedkin, Academy Award winning director of “The French Connection” and “The Exorcist;” Los Angeles Dodger Manager, Joe Torre; and Academy Award winning legend Al Pacino.

Firestein is considered the leading expert in the field of rheumatoid arthritis, a disabling and chronic disease affecting some 2.1 million Americans. His research focuses on the pathogenesis of rheumatoid arthritis and mechanisms of inflammation, and his studies have played a pivotal role in the development of the highly effective drugs to treat this crippling disease.

Dr. Gary Firestein Steps Down as Chief of Rheumatology, Allergy and Immunology; Dr. Robert Terkeltaub Named Interim Chief

Dr. Gary Firestein

Dr. Gary Firestein

Dr. Gary Firestein will step down as Chief of the Rheumatology, Allergy and Immunology division as of July 1, announced Dr. Ken Kaushansky, Helen M. Ranney Distinguished Professor and outgoing Chair of the Department of Medicine.

Dr. Firestein, who has been chief of the division since 1998, is making the move because of the increasing demands of his leadership responsibilities as Dean of Translational Medicine and Director of the Clinical and Translational Research Institute (CTRI) for UCSD Health Sciences.

“During the last 12 years, the division grew dramatically in both accomplishments and international visibility. This is due entirely to the incredibly creative faculty, our outstanding trainees, and the dedicated staff,” said Dr. Firestein.

“I want to express my thanks to Dr. Firestein for being such an outstanding division leader for the past 12 years,” said Dr. Kaushansky. “Under Gary’s leadership, the division has continued to grow and prosper in all three of its missions: research, education, and clinical care.

“The division has gone from unranked to a consistent top-20 ranking in the ‘America’s Best Hospitals’ list from U.S.News & World Report,” he said. “Its research portfolio has grown to be generally among the largest in the department.”

“Gary has also overseen the creation and expansion of the Center for Innovative Therapy as a model for translational medicine and helped bring in supporting program project grants,” Dr. Kaushansky said.

These include the NIH-funded Specialized Centers of Research program on rheumatoid arthritis, the Rheumatic Diseases Core Center grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and a new NIAMS Ruth L. Kirschstein T32 Training Grant to support research training in rheumatic diseases.

“Gary has also recruited a number of very successful research-oriented faculty into the Rheumatology and Allergy/Immunology sections,” Dr. Kaushansky said. “The division’s clinical mission has expanded to include a novel multidisciplinary clinic with the Department of Orthopaedics.

Dr. Robert Terkeltaub

Dr. Robert Terkeltaub

Dr. Robert A. Terkeltaub, Professor of Medicine, will serve as Interim Chief. For most of the last decade, Dr. Terkeltaub has served as Associate Director of the division and Director of the Rheumatology Training Program.

He has been Chief of the Rheumatology Section at the VA San Diego Healthcare System since 1985.

“I’m grateful to Dr. Robert Terkeltaub for agreeing to serve in the interim role,” said Dr. Kaushansky. “I know he will carry on the rich tradition of the division.”

“Dr. Terkeltaub is an outstanding physician-scientist who has played an integral role in the division’s success. We are truly grateful that he agreed to take on this new responsibility,” said Dr. Firestein.

“I look forward to helping the division through the transition period and into the future,” Dr. Terkeltaub said.

“We are very proud of our faculty and their accomplishments,” he said. “We want to ensure that the clinical programs remain strong and the clinical, translational, and basic research from our very accomplished faculty members grows in breadth, quality, and scope.”

Another goal, he said, is to increase the division’s interaction with other Department of Medicine divisions, including the three newest – Geriatrics, Global Public Health, and Biomedical Informatics.

About Dr. Terkeltaub

Dr. Terkeltaub received his M.D. degree and completed his internship, residency, and fellowship at McGill University in Montreal, Canada. From 1981 to 1984, he was a postdoctoral fellow in the laboratory of Dr. Mark Ginsberg at The Scripps Research Institute in La Jolla.

He spent the following year as a research associate at The Scripps Research Institute before he joined the UCSD faculty as Assistant Professor of Medicine in the Division of Rheumatology, Allergy and Immunology and Chief of the Rheumatology Section at the VA San Diego Healthcare System.

Dr. Terkeltaub has served on numerous study sections for the National Institutes of Health, the American Heart Association, the Arthritis National Research Foundation, and other organizations. He is currently Associate Editor of the journal Arthritis & Rheumatism.

As an investigator, Dr. Terkeltaub studies the interfaces of inflammation with skeletal and vascular biology, focusing on arthritis and vascular diseases, including infantile artery calcification, gout, and osteoarthritis. At the VA and UCSD, his lab discovered the molecular etiology of generalized artery calcification of infancy, and has done seminal research on innate immunity in gout, and on cartilage innate immunity and chondrocyte hypertrophy in osteoarthritis.

About Dr. Firestein

Dr. Gary Firestein first joined the UCSD Department of Medicine faculty in 1988 as Assistant Professor of Medicine in the Division of Rheumatology, Allergy and Immunology.

He spent 1992 through 1996 as Senior Director of Immunology for Gensia, Inc, and returned to UCSD as Associate Professor of Medicine in 1996. He was promoted to Professor of Medicine in 1998, when he was also appointed division chief.

On a personal note, Dr. Kaushansky said, “Gary was the only person I knew at UCSD when I started interviewing for the position here. We collaborated on a couple of papers back in our formative days.”

Those days were in the late 1980s, when Dr. Kaushansky was Assistant Professor in the Division of Hematology at the University of Washington and the younger Dr. Firestein was Assistant Professor in the Rheumatology, Allergy and Immunology division here at UCSD.

The two papers reported some of Dr. Firestein’s earliest work, with his mentor and then-division chief Dr. Nathan Zvaifler, on the presence of pro-inflammatory mediators in the synovial fluid of rheumatoid arthritis patients.

In the following years, Dr. Firestein’s basic science studies would open the way for the development of anti-cytokine agents as the first broadly effective treatments for rheumatoid arthritis.

Dr. Firestein was founding director of the UCSD Clinical Investigation Institute, a responsibility that has evolved into his current role as Director of the Clinical and Translational Research Institute.

He was appointed Dean of Translational Medicine for UCSD Health Sciences in 2008.

New York Times Health Guide Highlights Dr. Gary Firestein’s Work in Rheumatoid Arthritis

UCSD rheumatologist Dr. Gary S. Firestein is featured in a New York Times profile on current treatment and future research directions for rheumatoid arthritis.

Published in the New York Times Health Guide, the profile describes Dr. Firestein’s pioneering work in the use of tumor necrosis factor (TNF) blockers to treat rheumatoid arthritis.

Gary S. Firestein, M.D., is Professor of Medicine, Chief of the Division of Rheumatology, Allergy and Immunology and Dean of Translational Medicine at UCSD.

Read the New York Times article

More Information: